Brokerages Set Glaukos Corporation (GKOS) PT at $49.20

Glaukos Corporation (NYSE:GKOS) has been assigned an average recommendation of “Buy” from the nine research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $49.20.

Several equities analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Glaukos Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, May 2nd. TheStreet upgraded shares of Glaukos Corporation from a “d+” rating to a “c” rating in a report on Wednesday, March 1st. Cantor Fitzgerald restated an “overweight” rating and set a $54.00 target price on shares of Glaukos Corporation in a report on Thursday, May 4th. BMO Capital Markets reiterated a “buy” rating and issued a $54.00 price objective on shares of Glaukos Corporation in a report on Tuesday, April 11th. Finally, Stifel Nicolaus boosted their price objective on shares of Glaukos Corporation from $45.00 to $55.00 and gave the stock a “positive” rating in a report on Tuesday, February 28th.

Shares of Glaukos Corporation (GKOS) traded down 1.07% during mid-day trading on Tuesday, hitting $40.55. The stock had a trading volume of 503,373 shares. The company’s 50 day moving average price is $40.94 and its 200 day moving average price is $41.75. The stock has a market cap of $1.39 billion, a P/E ratio of 368.64 and a beta of 1.33. Glaukos Corporation has a 12-month low of $26.96 and a 12-month high of $52.49.

Institutional investors have recently modified their holdings of the company. State Street Corp raised its position in shares of Glaukos Corporation by 6.9% in the fourth quarter. State Street Corp now owns 281,407 shares of the medical instruments supplier’s stock worth $9,653,000 after buying an additional 18,183 shares in the last quarter. AQR Capital Management LLC purchased a new position in shares of Glaukos Corporation during the fourth quarter worth approximately $513,000. Russell Investments Group Ltd. purchased a new position in shares of Glaukos Corporation during the fourth quarter worth approximately $5,371,000. William Blair Investment Management LLC raised its position in shares of Glaukos Corporation by 5.3% in the first quarter. William Blair Investment Management LLC now owns 2,064,444 shares of the medical instruments supplier’s stock worth $105,906,000 after buying an additional 104,670 shares in the last quarter. Finally, Engineers Gate Manager LP purchased a new position in shares of Glaukos Corporation during the first quarter worth approximately $372,000. Hedge funds and other institutional investors own 89.39% of the company’s stock.

WARNING: This piece was posted by Markets Daily and is the property of of Markets Daily. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.themarketsdaily.com/2017/06/17/brokerages-set-glaukos-corporation-gkos-pt-at-49-20.html.

About Glaukos Corporation

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply